UNIverse - Public Research Portal

Selected Publications

Kaiser, Benedict, Miot, Sylvie, Wixmerten, Anke, Pullig, Oliver, Eyrich, Matthias, Fulco, Ilario, Vavrina, Josef, Schaefer, Dirk J., Martin, Ivan, Barbero, Andrea, & Haug, Martin D. (2024). Engineered autologous nasal cartilage for repair of nasal septal perforations: a case series [Journal-article]. International journal of surgery (London, England), 110(10), 6573–6580. https://doi.org/10.1097/JS9.0000000000001843

URLs

URLs

Majumder, Nilotpal, Roy, Chandrashish, Doenges, Laura, Martin, Ivan, Barbero, Andrea, & Ghosh, Sourabh. (2024). Covalent Conjugation of Small Molecule Inhibitors and Growth Factors to a Silk Fibroin-Derived Bioink to Develop Phenotypically Stable 3D Bioprinted Cartilage [Journal-article]. ACS Applied Materials and Interfaces, 16(8), 9925–9943. https://doi.org/10.1021/acsami.3c18903

URLs

URLs

Chaaban, Mansoor, Moya, Adrien, García-García, Andres, Paillaud, Robert, Schaller, Romain, Klein, Thibaut, Power, Laura, Buczak, Katarzyna, Schmidt, Alexander, Kappos, Elisabeth, Ismail, Tarek, Schaefer, Dirk J., Martin, Ivan, & Scherberich, Arnaud. (2023). Harnessing human adipose-derived stromal cell chondrogenesis in vitro for enhanced endochondral ossification [Journal-article]. Biomaterials, 303. https://doi.org/10.1016/j.biomaterials.2023.122387

URLs

URLs

García-García, Andrés, Pigeot, Sébastien, & Martin, Ivan. (2023). Engineering of immunoinstructive extracellular matrices for enhanced osteoinductivity. Bioactive Materials, 24, 174–184. https://doi.org/10.1016/j.bioactmat.2022.12.017

URLs

URLs

García-García, Andrés, Klein, Thibaut, Born, Gordian, Hilpert, Morgane, Scherberich, Arnaud, Lengerke, Claudia, Skoda, Radek C., Bourgine, Paul E., & Martin, Ivan. (2021). Culturing patient-derived malignant hematopoietic stem cells in engineered and fully humanized 3D niches. Proceedings of the National Academy of Sciences of the United States of America, 118(40). https://doi.org/10.1073/pnas.2114227118

URLs

URLs

Selected Projects & Collaborations

Direct 3D Bioprinting strategies to study articular cartilage development and regenerative therapy for osteoarthritis

Research Project | 2 Project Members

By the year 2030, approximately 25% of the adult population is projected to suffer from clinically diagnosed osteoarthritis (OA). At present OA cannot be treated, but only the associated pain is managed by administration of anti-inflammatory drugs. Implantation of tissue engineered cartilage in the affected lesions has been a hotly pursued research area worldwide for last three decades. However, this line of research has not succeeded so far. The most common problem encountered is that the engineered cartilage generated using mesenchymal progenitor cells (MSCs) does not share the molecular properties of native permanent cartilage but, instead, become vascularized, undergoes hypertrophic differentiation and eventually is replaced by bone once implanted in vivo. These latter features characterize both the transient cartilage (i.e.; cartilage formed at the epiphyseal growth plates of long bones) and the articular cartilage in OA joint. The overall objective of this proposal is to engineer a cartilage tissue which will be molecularly indistinguishable from healthy articular cartilage and which remains phenotypically stable also when implanted in a OA environment. We propose a comprehensive plan to achieve this, at the core of which is to engineer developmental processes in order to control fate specification by MSC and developing functional cartilage tissue construct by 3D bioprinting.Working hypothesis. Most of the tissue engineering studies did not take into account: (i) the natural process of permanent cartilage differentiation; (ii) the molecular niche in native permanent cartilage and the changes it undergoes during OA; (iii) the nature of the engineered cartilage; (iii) the effect that the niche, particularly the altered one in OA, has on tissue engineered cartilage. In the current proposal, we will develop a comprehensive strategy for designing a disease modifying therapy of OA, combining our strengths in 3D bioprinting, biomedical engineering, microfluidics and joint cartilage developmental biology. We hypothesize that phenotypical stable cartilage can be engineered by culturing MSC with signalling proteins (i.e.: Wnt ligands) and morphogenetic inhibitors (BMP inhibitors) recently shown (mainly by the applicants) to be key in regulating differentiation of MSC into stable or transient cartilage. Specific aims & experimental design. The first aim is to generate 3D bioprinted permanent cartilage in vitro. For this purpose, we will initially perform a screening of different doses and temporal stages of supplementation of Wnt ligands and BMP inhibitor within a microfluidic platform allowing generating and perfusing 3D MSCs microaggregates. This will allow identify the most promising conditions enabling the differentiation of MSCs into stable cartilage, to be scaled up and applied into the 3D bioprinted constructs. We will then explore use of silk-gelatin bioink tethered pathway-regulatory molecules on differentiation of the encapsulated mesenchymal cells (Aim 1). Once this is achieved, we will work towards two distinct but complementary approaches: (i) We will develop an in vitro model for OA. For this we will activate BMP signalling in the 3D bioprinted permanent cartilage to investigate if it recapitulates changes associated with OA. This will allow us to create a platform for rapid screening of drugs or other bioactive molecules which may be therapeutically relevant (Aim2). We will then develop bioink which will be either sensitive to matrix metalloproteases or mechanical stimulation to release in situ BMP inhibitors to protect the 3D bioprinted permanent cartilage once implanted in an OA joint (induced in mice), environment which would instead promote transient cartilage differentiation (Aim 3).Expected value of the proposed project. Even after 30 years of efforts, fabrication of load bearing and clinically relevant, biochemically equivalent cartilage tissue constructs still remains elusive. We are aware that this is a novel and highly ambitious objective, but collectively we have the necessary expertise and insight to attempt this, which if achieved will surely be a major boost for developing a disease modifying therapy for OA.

Engineering of cell-free extracellular matrices enriched with osteoinductive and immunomodulatory factors to enhance bone healing

Research Project | 2 Project Members

Infection, trauma or tumors can generate critical bone defects with compromised regeneration capacity, still not resolvable through clinical gold standard solutions. Extracellular matrices (ECMs) have been proposed for the physiological presentation of various cytokines at sites of tissue repair to activate and regulate endogenous cells. ECMs do not need to be derived from native tissues, but can be tissue-engineered and then devitalized. This provides the potential advantages of standardization (e.g., thanks to the use of cell lines) and of customization (e.g., by transducing cells to overexpress defined factors). ECMs could be engineered to deliver not only osteoinductive factors, but also immunomodulatory signals, which are increasingly being recognized as strong regulators in bone regeneration. Working hypothesis. We hypothesize that engineered and devitalized ECMs, specifically enriched in osteoinductive factors (BMP-2), as well as in cytokines polarizing immune response towards a pro-regenerative phenotype (IL4) and resolving acute inflammation (IL1Ra), can enhance bone regeneration. Specific aims. In order to generate the modular bricks for the engineering of ECMs, cell lines expressing different instructive cues (BMP-2, IL4 and IL1Ra) will be derived from an existing death-inducible human mesenchymal cell line (MSOD) (Aim1). ECMs enriched with different combinations and doses of such cues will be engineered, characterized and tested in a standard ectopic implantation model (Aim2). The capacity of these ECMs in modulating human immune cell recruitment and polarization will be investigated in vitro (Aim3). The effect of signals presented by ECMs on bone repair and the possible role of macrophages and T cells will be investigated in a rat critical sized calvarial defect (Aim4).Experimental design. Three cell lines will be generated by lentivirally transducing the MSOD line to express BMP2, IL4 and IL1Ra under the control of inducible promoters, and characterized in vitro for secretion of factors, proliferation, differentiation capacity and death-induction responsiveness (Aim1). Generated cell lines will be cultured on collagen scaffolds within a perfusion bioreactor to engineer ECMs, enriched in the different instructive signals. Obtained ECMs will be assessed for protein content and release, compatibility with inducible apoptosis and osteoinductive potential (Aim2). The immunomodulatory effect of engineered ECMs will be evaluated in an in vitro human setup based on i) chemokine release profiles, ii) recruitment and polarization of macrophages and iii) macrophage-mediated polarization of T cells (Aim3). The capacity of engineered ECMs to enhance bone repair will be studied in critical sized calvarial bone defects in immunocompetent rats, with or without depletion of T cells (Aim4). Expected value of the proposed project. Our studies will lead to the establishment of a strategy to engineer cell-free customizable materials presenting specific signals crucial for tissue regeneration. Moreover, our research will allow gaining new insights on the possibility to enhance bone healing by modulating inflammation and immunity. Such knowledge will be instrumental to improve the design of biomaterials/drugs in the broader field of regenerative immunology.